3320 — China Resources Pharmaceutical Balance Sheet
0.000.00%
Last trade - 00:00
- HK$30.28bn
- HK$99.43bn
- CNY244.70bn
- 82
- 97
- 43
- 91
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34,789 | 38,587 | 47,067 | 46,522 | 59,266 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 56,662 | 55,927 | 62,772 | 67,872 | 75,572 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 118,809 | 123,819 | 143,903 | 152,259 | 178,568 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 19,754 | 19,266 | 20,804 | 22,092 | 25,376 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 169,822 | 176,225 | 202,531 | 215,534 | 246,770 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 95,331 | 103,207 | 115,151 | 121,770 | 134,233 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 133,439 | 137,112 | 160,991 | 171,977 | 200,811 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 36,383 | 39,113 | 41,540 | 43,557 | 45,960 |
Total Liabilities & Shareholders' Equity | 169,822 | 176,225 | 202,531 | 215,534 | 246,770 |
Total Common Shares Outstanding |